Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study-Reference-Cited by-全球学者库

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Published:2019-09 Issue:9 Volume:20 Page:1239-1251
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Robert Caroline,Ribas Antoni,Schachter Jacob,Arance Ana,Grob Jean-Jacques,Mortier Laurent,Daud Adil,Carlino Matteo S,McNeil Catriona M,Lotem Michal,Larkin James M G,Lorigan Paul,Neyns Bart,Blank Christian U,Petrella Teresa M,Hamid Omid,Su Shu-Chih,Krepler Clemens,Ibrahim Nageatte,Long Georgina V

Funder

Merck

Meso Scale Diagnostics

Roche

Merck Sharp and Dohme

Les Laboratories Pierre Fabre

British Microcirculation Society

Amgen

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

3. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial;Ascierto;JAMA Oncol,2018

4. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial;Larkin;J Clin Oncol,2018

5. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma;Ribas;JAMA,2016

Cited by 774 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis;Computational and Structural Biotechnology Journal;2024-12

2. Gene engineered exosome reverses T cell exhaustion in cancer immunotherapy;Bioactive Materials;2024-04

3. SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma;Immunotherapy;2024-03

4. Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance;Drug Resistance Updates;2024-03

5. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy;European Journal of Cancer;2024-03